IEM 1925 dihydrobromide

Pricing Availability   Qty

Save up to 40% on RUO Reagents with BIOSPRING24 (see details)

Description: Voltage- and use-dependent open-channel AMPA blocker
Chemical Name: N-(1-Phenylcyclohexyl)-1,5-pentanediamine dihydrobromide
Purity: ≥95% (HPLC)
Citations (2)
Literature (5)

Biological Activity for IEM 1925 dihydrobromide

IEM 1925 dihydrobromide is a voltage- and use-dependent open-channel antagonist of AMPA receptors. Selective between subtypes; blocks GluA2 subunit-lacking receptors more potently than GluA2-containing receptors (KD for GluA2-containing AMPAR is 210 times higher at -80 mV). More potent than IEM 1460 (Cat. No. 1636) and IEM 1754 due to a slower unblocking rate. Alleviates inflammatory pain in a rat model of peripheral inflammation.

Technical Data for IEM 1925 dihydrobromide

M. Wt 422.24
Formula C17H28N2.2HBr
Storage Desiccate at RT
Purity ≥95% (HPLC)
CAS Number 258282-23-4
PubChem ID 44561101

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for IEM 1925 dihydrobromide

Solvent Max Conc. mg/mL Max Conc. mM
water 42.22 100
DMSO 21.11 50

Preparing Stock Solutions for IEM 1925 dihydrobromide

The following data is based on the product molecular weight 422.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.37 mL 11.84 mL 23.68 mL
5 mM 0.47 mL 2.37 mL 4.74 mL
10 mM 0.24 mL 1.18 mL 2.37 mL
50 mM 0.05 mL 0.24 mL 0.47 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for IEM 1925 dihydrobromide

References for IEM 1925 dihydrobromide

References are publications that support the biological activity of the product.

Tikhonov et al (2000) Voltage-dependent block of native AMPA receptor channels by dicationic compounds. Br.J.Pharmacol. 129 265 PMID: 10694232

Kopach et al (2016) Inhibition of spinal Ca2+-permeable AMPA receptors with dicationic compounds alleviates persistent inflammatory pain without adverse effects. Front.Cell Neurosci. 10 PMID: 26973464

If you know of a relevant reference for IEM 1925 dihydrobromide, please let us know.

View Related Products by Target

View Related Products by Product Action

View all AMPA Receptor Antagonists

Keywords: IEM 1925 dihydrobromide, IEM 1925 dihydrobromide supplier, IEM1925, 2HBr, AMPAR, antagonist, blocks, AMPA, receptor, voltage-dependent, channel, blocker, Receptors, 4198, Tocris Bioscience

2 Citations for IEM 1925 dihydrobromide

Citations are publications that use Tocris products. Selected citations for IEM 1925 dihydrobromide include:

Terunaga et al (2023) Modulatory mechanisms of TARP γ8-selective AMPA receptor therapeutics. Nat Commun 14 1659 PMID: 36966141

Ondrej et al (2021) Gating and modulation of a hetero-octameric AMPA glutamate receptor. Nature 594 454-458 PMID: 34079129

Do you know of a great paper that uses IEM 1925 dihydrobromide from Tocris? Please let us know.

Reviews for IEM 1925 dihydrobromide

There are currently no reviews for this product. Be the first to review IEM 1925 dihydrobromide and earn rewards!

Have you used IEM 1925 dihydrobromide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.